Fibroblast Growth Factors (Fgfs) Market Report For M&A, Expansion, And Competitive Benchmarking (20252034)

The Business Research Company

The Business Research Company's Fibroblast Growth Factors (FGFs) Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, July 2, 2025 /EINPresswire / -- The robust growth of the fibroblast growth factors FGFs market industry has been the talk of the town. As per the Fibroblast Growth Factors FGFs Global Market Report 2025, the market, which was valued at $3.75 billion in 2024, is set to see a leap to $4.11 billion in 2025, reflecting a compound annual growth rate CAGR of 9.5%.

How Is The Fibroblast Growth Factors FGFs Market Faring, And What Are Its Growth Prospects?
The fibroblast growth factors FGFs market has grown remarkably in recent years, a trend that is predicted to continue in the future. The market size is expected to burgeon to $5.84 billion in 2029, growing at a CAGR of 9.2%. Factors contributing to this growth include rising investments in personalized medicine, increased adoption of fibroblast growth factors FGFs-based therapies, prevalence of chronic diseases, advancements in biotechnology, and collaborations between pharma and research institutes. Notably, growth trends for the forecast period are identified as advancements in targeted drug delivery, development of advanced biomaterials for FGFs delivery, innovation in gene editing technologies, advancements in sustained-release formulations, and innovation in combination therapies.

Get Your Free Sample Market Report:

What Macro Factors Are Driving The Fibroblast Growth Factors FGFs Market Growth?
An important growth driver propelling the fibroblast growth factors FGFs market is the escalating prevalence of chronic diseases. These long-term health conditions develop gradually and often require continuous medical attention. The rise in such diseases can be partially attributed to sedentary lifestyles which increase the risk of heart conditions and diabetes. FGFs play a crucial role in managing these chronic diseases by promoting tissue repair and regeneration. They advance the healing process, slow down disease progression and help improve patient outcomes as well as their quality of life. For instance, according to the National Health Service, a UK-based government department, approximately 3,615,330 individuals registered with a general practitioner GP were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, a significant 18% increase from 3,065,825 cases in 2022.

Who Are The Major Players In The Fibroblast Growth Factors FGFs Market?
Industry titans in the fibroblast growth factors FGFs market include Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Wako Pure Chemical Corporation, Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, 89bio Inc., R&D Systems Inc., ACROBiosystems Co. Ltd., Elabscience Biotechnology Inc., Cell Signaling Technology Inc., BPS Bioscience Inc., Proteintech Group Inc., Akero Therapeutics Inc., MedChemExpress LLC, Defined Bioscience Inc., Gold Biotechnology Inc. GoldBio, Nucleus Biologics LLC, ZellBio GmbH, Affinity Biosciences Ltd., and GeneCards.

Order Your Report Now For A Swift Delivery:

What Are Exciting Trends Emerging In The Fibroblast Growth Factors FGFs Market Industry?
Major players in the fibroblast growth factors FGFs market are increasingly focusing on technological advancements, such as developing engineered FGF variants, to enhance therapeutic efficacy. These engineered fibroblast growth factor FGF variants are essentially modified forms of fibroblast growth factors that seek to improve stability, specificity, and potency, thereby ensuring better outcomes in tissue regeneration and disease treatment. For instance, in October 2022, Zhittya Genesis Medicine, a US-based biotechnology company, introduced novel FGF-1 therapy for treating Parkinson's disease. This therapy uses intranasal delivery to promote angiogenesis and neuronal regeneration in the brain, paving the way for new advancements in disease management.

How Is The Fibroblast Growth Factors FGFs Market Segmented ?
The fibroblast growth factors FGFs market includes diverse segments:
1 By Product Type: Recombinant Fibroblast Growth Factor, Purified Fibroblast Growth Factor, Endogenous Fibroblast Growth Factor, Other Product Types
2 By Type: Palifermin, Erdafitnib, Infigratinib, Futibatinib, Other Types
3 By Application: Oncology, Hematology, Wound Healing, Dermatology, Cardiovascular Disease, Bone Disorders, Musculoskeletal Disorders, Tissue Regeneration, Other Applications
4 By End User: Pharmaceutical Companies, Research Institutes, Biotechnology Companies, Other End Users.

What Does The Scenario Look Like Regional-Wise In The Fibroblast Growth Factors FGFs Market?
In 2024, North America was the largest region for the fibroblast growth factors FGFs market, while Asia-Pacific is projected to be the fastest-growing region in the near future. The market report comprehensively covers regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Follicle Stimulating Hormone Global Market Report 2025

Hair Growth Serum Global Market Report 2025

Uterine Fibroids Treatment Global Market Report 2025

About The Business Research Company :
With a repository of over 15000+ reports across 27 industries and spanning 60+ geographies, The Business Research Company has built an impressive reputation for comprehensive, data-rich research and insights. Leveraging over 1,500,000 datasets, in-depth secondary research, and unique industry leader insights, we provide the information you need to stay ahead in the game.

Get in touch:
Website:
Americas - +1 310-496-7795
Asia: +44 2071930708
Europe - +44 7882 955267
Email: ...

Follow us:
LinkedIn:
YouTube:
Global Market Model: global-market-model

Oliver Guirdham
The Business Research Company
+44 7882 955267
...
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MENAFN02072025003118003196ID1109751165